![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
New HCV Protease Inhibitor:a phase 1/2a Study of Safety, Tolerability and Pharmacokinetic Profiles of TG-2349, a Pan-Genotypic HCV Protease Inhibitor, in Healthy East Asian and Caucasian Subjects, and its Antiviral Activity in Chronic Hepatitis C patients.
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-5 Wash DC
![AASLD1.gif](../images/120413/120413-10/AASLD1.gif)
![AASLD2.gif](../images/120413/120413-10/AASLD2.gif)
![AASLD3.gif](../images/120413/120413-10/AASLD3.gif)
![AASLD4.gif](../images/120413/120413-10/AASLD4.gif)
![AASLD5.gif](../images/120413/120413-10/AASLD5.gif)
![AASLD6.gif](../images/120413/120413-10/AASLD6.gif)
![AASLD7.gif](../images/120413/120413-10/AASLD7.gif)
![AASLD8.gif](../images/120413/120413-10/AASLD8.gif)
![AASLD9.gif](../images/120413/120413-10/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|